Clinical trial • Phase I • Oncology
Clinical trial in T-cell non-Hodgkin lymphoma | Cutaneous T-cell lymphoma | Peripheral T-cell lymphoma
Phase I trial for T-cell non-Hodgkin lymphoma | Cutaneous T-cell lymphoma | Peripheral T-cell lymphoma. 38 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- T-cell non-Hodgkin lymphoma | Cutaneous T-cell lymphoma | Peripheral T-cell lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 08-12-2025
- First CTIS Authorization Date
- 01-04-2026
Trial design
Phase I trial across 8 sites in Italy, Spain.
- Target Sample Size
- 38
Recruitment
- Planned Sample Size
- 38
- Recruitment Window Months
- 56
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 34
Italy
- Earliest CTIS Part Ii Submission Date
- 09-03-2026
- Latest Decision Or Authorization Date
- 01-04-2026
- Processing Time Days
- 23
- Number Of Sites
- 4
- Number Of Participants
- 17
Sites
- Site Name
- Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
- Department Name
- ITL003: Oncologia Medica ed Ematologia
- Contact Person Name
- Umberto Vitolo
- Contact Person Email
- umberto.vitolo@ircc.it
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- ITL004: UOC Ematologia
- Contact Person Name
- Pier Luigi Zinzani
- Contact Person Email
- pierluigi.zinzani@unibo.it
- Site Name
- Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
- Department Name
- ITL001: Ematologia
- Contact Person Name
- Giuseppe Gritti
- Contact Person Email
- giuseppe_gritti@yahoo.it
- Site Name
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
- Department Name
- ITL002: Ematologia Universitaria
- Contact Person Name
- Federica Cavallo
- Contact Person Email
- f.cavallo@unito.it
Spain
- Earliest CTIS Part Ii Submission Date
- 19-03-2026
- Latest Decision Or Authorization Date
- 06-04-2026
- Processing Time Days
- 18
- Number Of Sites
- 4
- Number Of Participants
- 17
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- ESP002: Hematología
- Contact Person Name
- Pablo Mozas
- Contact Person Email
- mozas@clinic.cat
- Site Name
- Clinica Universidad De Navarra
- Department Name
- ESP001: Hematology and Hemotherapy
- Contact Person Name
- Miguel Canales Albendea
- Contact Person Email
- macanales@unav.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- ESP004: Hematología
- Contact Person Name
- Miguel Canales Albendea
- Contact Person Email
- macanales@unav.es
- Site Name
- Institut Catala D'oncologia
- Department Name
- ESP003: Hematologia
- Contact Person Name
- Eva Domingo Domenech
- Contact Person Email
- edomingo@iconcologia.net
Sponsor
Primary sponsor
- Full Name
- Kyowa Kirin Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)